92型医薬品はEUの承認を得て,国際市場で脳卒中治療製品の扉を開く. Route 92 Medical gains EU approval, opening doors for stroke treatment products in international markets.

サンマテオに本拠を置くRoute 92 Medicalは,神経血管介入製品に対するEU承認とMDSAPの認可を受け,欧州や他の国際市場への参入を可能にしました. Route 92 Medical, a San Mateo-based company, has received EU approval and MDSAP clearance for its neurovascular intervention products, enabling entry into European and other international markets. カテーテルやリゾリューションシステムを含む株式会社製品は,脳卒中治療の改善を目指す. The company's products, which include catheters and reperfusion systems, aim to improve stroke treatment. CEOのトニー・コー博士が率いる 会社のグローバル展開に 重要な一歩を踏み出しています This certification marks a significant step in the company's global expansion, led by CEO Dr. Tony Chou.